Mark Fisher, MD
Rheumatology · Haddon Heights, NJNPI 1609961937
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Amgen at 24.3% of the total.
Across 285 payments — averaging $14.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$988
- AbbVie$819
- Johnson & Johnson$419
- Pfizer$317
- GSK$273
- Lilly USA, LLC$216
- plus $1K from 17 others
Across 4 payments — averaging $7166.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$29K
What the payments were for
- Food & beverage$3,98898%
- Education$702%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 71 | $988 |
| AbbVie | 50 | $819 |
| Johnson & Johnson(2 entities) | 30 | $419 |
| Pfizer | 26 | $317 |
| GSK | 21 | $273 |
| Lilly USA, LLC | 19 | $216 |
| UCB, Inc. | 13 | $175 |
| Genentech USA, Inc. | 4 | $115 |
| AstraZeneca | 8 | $112 |
| Novartis | 6 | $85 |
| Mallinckrodt Enterprises LLC | 5 | $66 |
| Boehringer Ingelheim | 4 | $63 |
| Merck | 5 | $60 |
| Organon | 4 | $56 |
| ANI Pharmaceuticals, Inc. | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 4 | $50 |
| Mallinckrodt Hospital Products Inc. | 3 | $43 |
| Radius Health, Inc. | 2 | $42 |
| Pacira Therapeutics, Inc. | 3 | $40 |
| Bioventus LLC | 1 | $28 |
| Aurinia Pharma U.S., Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Sanofi | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$122
How this compares
$4,058 in reported general payments places this provider in the 55th percentile of 234 rheumatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 25 | $205,533 |
| Xeljanz XrTofacitinib Citrate | 34 | $190,672 |
| EnbrelEtanercept | 26 | $189,459 |
| Enbrel MiniEtanercept | 21 | $155,165 |
| RinvoqUpadacitinib | 13 | $78,957 |
| MethotrexateMethotrexate Sodium | 132 | $3,329 |
| Hydroxychloroquine Sulfate | 37 | $2,373 |
| Leflunomide | 41 | $1,472 |
| Prednisone | 178 | $1,325 |
| Gabapentin | 34 | $1,166 |
| Tizanidine Hcl | 54 | $731 |
| Nabumetone | 21 | $706 |
| Sulfasalazine | 19 | $513 |
| Azathioprine | 19 | $476 |
| Famotidine | 34 | $445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $988 | $189,45926 claims |
| AbbVieRinvoq | $819 | $78,95713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 234 rheumatology providers in New Jersey.
Other rheumatology in Haddon Heights
- Lori CoxNew Brunswick$1.4M
- Richard HaddadRed Bank$1.1M
- Kiren SahniWest Long Branch$569K
- Jeffrey GreenbergSummit$399K
- Steven GolombekDover$318K
- Nicholas ScarpaJersey City$281K
- Adrienne HollanderVoorhees$214K
- Edward AllegraRed Bank$212K
- Nickolas TyrisSewell$201K
- Anan HaijaGalloway$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.